Beovu Pre-filled Syringe for Wet AMD and DME Treatment

Beovu Pre-filled Syringe contains brolucizumab, an anti-VEGF eye injection used to treat neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). It is given by a retina specialist as an intravitreal injection to reduce fluid, swelling, and leakage in the retina and help maintain or improve vision. You order through YouDrugstore and we coordinate shipment from trusted partner pharmacies to your US address.

What Beovu Is and How It Works

Beovu (brolucizumab) is a monoclonal antibody fragment that binds vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, it decreases abnormal blood vessel growth and leakage in the macula. The medicine is supplied as a single-use, intravitreal pre-filled syringe for injection by an eye care professional.

Approved uses include wet AMD and DME. For both conditions, patients start with a loading phase and then move to maintenance intervals that can extend based on disease control. The goal is to keep the retina dry, stabilize vision, and reduce injection frequency when possible.

We coordinate sourcing and shipping through licensed, vetted international partner pharmacies, supplying authentic brand products with a broad selection at competitive prices.

Dosage and Usage

The dose is 6 mg (0.05 mL) delivered as a single intravitreal injection using the pre-filled syringe. A trained ophthalmologist administers each dose under aseptic conditions.

Typical schedules:

• Wet AMD: One injection every month for the first 3 doses, then every 8 to 12 weeks based on disease activity.
• DME: One injection every 6 weeks for the first 5 doses, then every 8 to 12 weeks based on disease activity.

Your specialist may use a treat-and-extend approach. Interval length depends on imaging, fluid status, and vision results.

Missed dose guidance:

• If a scheduled injection is missed, contact the retina clinic to reschedule as soon as possible.
• Do not self-inject or attempt to make up a missed dose on your own.

Storage and handling:

• Store refrigerated at 2 to 8 C (36 to 46 F). Do not freeze.
• Keep the syringe in the original carton to protect from light.
• Do not shake. Do not use if damaged, discolored, or expired.
• For your appointment, transport it in an insulated bag with cold packs if requested by the clinic.
• Let the syringe reach room temperature in the clinic before use, as directed by the provider.

Travel tips:

• Use a small cooler with gel packs for trips to the clinic.
• Do not place the syringe directly on ice; avoid freezing.
• Keep the carton upright and secure during travel.

Benefits and Savings

Beovu helps reduce retinal fluid and swelling, which can stabilize or improve vision in wet AMD and DME. The pre-filled syringe saves clinic prep time and supports accurate dosing. After loading, many patients extend to 8 to 12 week intervals, which may reduce the number of clinic visits over time.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba that follows Canadian pharmacy standards. Orders are reviewed by licensed pharmacists before dispensing through our partner pharmacies. We offer brand and generic medicines at Canadian prices and also carry OTC health products, with easy online ordering and customer-service chat during posted office hours.

Buying through YouDrugstore can provide meaningful savings compared to typical US pharmacy prices, often in the 60 to 80 percent range depending on the product and pack size. You can request multi-month supplies when appropriate, which may lower the per-month cost.

Side Effects and Safety

Most patients tolerate Beovu, but injection-site and ocular events can occur. Seek urgent care for severe symptoms after an injection.

• Common: eye pain or irritation, floaters, blurred vision, conjunctival hemorrhage (small red spot), mild increase in eye pressure.
• Less common but serious: endophthalmitis (eye infection), retinal vasculitis or retinal artery occlusion, severe intraocular inflammation, sudden vision loss, persistent severe eye pain, photophobia, large floaters or flashes.
• Systemic hypersensitivity reactions are rare. Report any severe rash, swelling, or breathing difficulty.

Contraindications include active ocular infection or intraocular inflammation, and known hypersensitivity to brolucizumab or excipients. The provider checks intraocular pressure and uses sterile technique at each visit. Patients with a history of retinal vasculitis or occlusive events may require extra caution or alternative therapy.

Data in pregnancy and lactation are limited. Discuss risks and timing with the specialist if pregnant, planning pregnancy, or breastfeeding.

Onset Time

Anatomical improvements, such as reduction in retinal fluid on OCT imaging, may appear within the first few weeks. Vision gains often develop over the first 1 to 3 months during the loading phase. Some patients maintain vision with extended dosing afterward, while others need closer intervals based on disease activity.

Compare With Alternatives

Several anti-VEGF agents treat wet AMD and DME:

Eylea (aflibercept): A widely used option for both wet AMD and DME. Many patients maintain 8-week or longer intervals after loading. Learn more about Eylea if your specialist is considering a change.

Lucentis (ranibizumab): Approved for wet AMD and DME. Often dosed every 4 weeks initially, then extended based on response. Some providers use biosimilars, where available, to improve cost access.

Vabysmo (faricimab): Targets both VEGF-A and Ang-2. It is used in wet AMD and DME with potential for longer intervals in selected patients.

Choice depends on prior response, safety considerations, dosing goals, and coverage or out-of-pocket cost. Beovu has a known risk of intraocular inflammation and rare retinal vasculitis or occlusive events; providers weigh these risks against potential benefits and interval flexibility. Patients sometimes switch between agents if drying is incomplete or if side effects occur.

Combination Therapy

Anti-VEGF monotherapy is standard for wet AMD and DME. In selected cases, providers may consider combination strategies, such as adding focal/grid laser for DME or photodynamic therapy for certain choroidal lesions. Nutritional support with AREDS2 formulas may be used for non-exudative AMD, but it does not replace anti-VEGF therapy for wet AMD. Treatment plans are individualized by the retina specialist.

Patient Suitability and Cost-Saving Tips

Beovu may suit adults diagnosed with wet AMD or DME who can attend regular follow-up and monitoring. It is not used when there is an active eye infection or intraocular inflammation. Careful evaluation is needed for those with a history of inflammatory eye disease or retinal vascular occlusions. Discuss timing if pregnant, planning pregnancy, or breastfeeding.

For cost planning, ordering a multi-month supply when your treatment interval is stable can reduce per-dose shipping cost. You can set simple reorder reminders so you never miss a clinic date. If paying out of pocket or with no insurance, Canadian pricing can ease the monthly cost of therapy.

For education on the disease itself, see the condition overview for Age Related Macular Degeneration. Your specialist will decide the schedule and follow-up testing based on your imaging and vision targets.

Authoritative Sources

Review official information before starting or switching therapy:

• Novartis Beovu product page
• FDA Prescribing Information for Beovu (brolucizumab)
• Health Canada Drug Product Database entry for Beovu

Ready to order? YouDrugstore helps arrange your prescription order with partner pharmacies and ships to your door in the US with prompt, express, cold-chain shipping to protect temperature-sensitive items.

Disclaimer: This page offers general information and is not medical advice. Talk with your eye care professional about diagnosis, risks, and the right dosing schedule for your situation. Always follow the injection and follow-up plan set by your specialist.